Seeking Alpha

Arrowhead Research Corporation (ARWR)

  • Wed, Aug. 26, 6:57 PM
    • Biotech analysts at Piper Jaffray say they are buyers on weakness of four biotech names - Vertex Pharma (NASDAQ:VRTX), Novavax (NASDAQ:NVAX), Alnylam Pharma (NASDAQ:ALNY) and Arrowhead Research (NASDAQ:ARWR) - that boast strong enough balance sheets to make it through upcoming value-driving events.
    • The firm notes VRTX holds more than $1B in cash, and expects a dramatic increase in treatable cystic fibrosis patients with the newly approved Orkambi, which will help drive revenue growth and a return to near-term profitability.
    • Jaffray says it has increased confidence in NVAX following positive Phase 2 data in its RSV-F in elderly subjects; the company ended the quarter with $315M in cash, which can fund "at least one" pivotal RSV trial.
    • ALNY ended the recent quarter with $1.4B in cash, with key patisiran and revusiran Phase II in OLE updates expected in Q4.
    • On ARWR, the firm looks to an expected September update of Phase IIa HEPARC 2001 data.
  • Tue, Aug. 4, 4:04 PM
    • Arrowhead Research (NASDAQ:ARWR): FQ3 EPS of -$0.27 beats by $0.11.
    • Revenue of $0.12M (+200.0% Y/Y) beats by $0.01M.
    • Press Release
    | Comment!
  • Wed, Jun. 17, 5:37 PM
    | 1 Comment
  • Wed, Jun. 10, 12:57 PM
    • The FDA designates Arrowhead Research's (ARWR +2.8%) ARC-AAT an Orphan Drug for the treatment of liver disease associated with Alpha-1 Antitrypsin Deficiency, a rare genetic disease that severely damages the liver and lungs.
    • ARC-AAT, currently in Phase 1 development, is an RNAi-based therapeutic which reduces the liver's production of mutant AAT protein.
    • Among the benefits of Orphan Drug status is a seven-year period of market exclusivity for the indication, if approved.
  • Tue, May 12, 10:21 AM
    • Arrowhead Research (ARWR -4.7%) FQ2 results: Revenues: $43.8K (unch); R&D Expense: $11.6M (+123.1%); SG&A: $1.7M (+30.8%); Operating Loss: ($29.6M) (-164.3%); Net Loss: ($28.7M) (-105.0%); Loss Per Share: ($0.51) (-64.5%); Quick Assets: $96.4M (-7.3%).
    • No guidance given.
  • Mon, May 11, 4:07 PM
    • Arrowhead Research (NASDAQ:ARWR): FQ2 EPS of -$0.51 misses by $0.17.
    • Revenue of $0.04M (flat Y/Y) misses by $0.07M.
    • Press Release
    | Comment!
  • Wed, Apr. 15, 1:32 PM
    • UnitedHealth Group (UNH -2.5%) upgraded to Buy with a $141 (21% upside) price target by Jefferies.
    • AbbVie (ABBV +1.1%) upgraded to Outperform with a $68 (9% upside) price target by BMO Capital Markets. Analyst Alex Arfaei cites improved prospects for Imbruvica and increased confidence that the company can defend Humira against biosimilars.
    • Clovis Oncology (CLVS +7.3%) upgraded to Buy with a $117 (27% upside) price target by Goldman Sachs.
    • NuVasive (NUVA -4%) downgraded to Hold with a $49 (14% upside from today's down move) price target by Cannaccord Genuity.
    • Arrowhead Research (ARWR -3.3%) downgraded to Hold with a $9 (28% upside from today's down move) price target by Jefferies.
    • Cellular Dynamics (ICEL +0.1%) downgraded to Market Perform with a $16.50 price target by Leerink Swann (unsurprising since the company is being acquired by Fujifilm for $16.50).
  • Tue, Apr. 14, 12:45 PM
  • Tue, Apr. 14, 9:12 AM
    | Comment!
  • Mon, Apr. 13, 9:15 AM
    | Comment!
  • Mon, Apr. 13, 7:53 AM
    • The FDA gives the green light to Arrowhead Research (NASDAQ:ARWR) to initiate a Phase 2b study of ARC-520 for the treatment of chronic hepatitis B infection. The study, called Heparc-2004, will involved 12 patients, eight will receive 1 mg/kg of ARC-520 and four will receive placebo.
    • The trial is designed to assess multiple doses of ARC-520 (2 mg/kg and 4 mg/kg) but FDA has a partial clinical hold in place until it reviews data from the 1 mg/kg arm.
    • The company expects to begin patient enrollment in ~1 month.
    • Previously: Arrowhead drops after FDA partial clinical hold on hep B candidate (Jan. 12)
  • Thu, Mar. 5, 9:15 AM
  • Thu, Mar. 5, 8:06 AM
    • Arrowhead Research (NASDAQ:ARWR) acquires Novartis' (NYSE:NVS) RNA interference (RNAi) R&D portfolio and associated assets, including certain patents and patent applications, an exclusive license to other patents and patent applications owned or controlled by Novartis, the assignment of a third party license and three preclinical product candidates.
    • Specific assets include multiple patent families covering RNAi-trigger design rules and modifications that fall outside of competitors' patents which provides Arrowhead freedom to operate for any target or indication, the assignment of Novartis' license from Alnylam (NASDAQ:ALNY) that gives Arrowhead access to Alnylam IP, excluding delivery, covering 30 gene targets and three product candidates with varying amounts of preclinical data.
    • Under the terms of the agreement, Arrowhead will pay $10M in cash (includes $7M paid previously) and $25M in ARWR stock within 30 days. Novartis is eligible to receive milestones and single-digit royalties on net sales.
    • Arrowhead will host a conference call this morning at 8:30 am to discuss the deal.
    | 1 Comment
  • Mon, Feb. 9, 4:03 PM
    • Arrowhead Research Corporation (NASDAQ:ARWR): FQ1 EPS of -$0.41 misses by $0.07.
    • Revenue of $0.17M (+325.0% Y/Y)
    • Press Release
  • Mon, Feb. 2, 4:15 PM
    • Arrowhead Research (NASDAQ:ARWR) will report fiscal Q1 results on February 9 after the close. The conference call will begin at 4:30 pm ET.
  • Thu, Jan. 22, 9:15 AM
    | 1 Comment
Visit Seeking Alpha's
ARWR vs. ETF Alternatives
Company Description
Arrowhead Research Corp is engaged in developing novel drugs to treat intractable diseases by silencing the genes. The Company's drug candidate ARC-520 is designed to treat chronic hepatitis B infection.
Sector: Healthcare
Industry: Biotechnology
Country: United States